Silverback Therapeutics, Inc. (SBTX)

Investigation 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Silverback Therapeutics, Inc. ("Silverback” or the "Company") (NASDAQ: SBTX). The investigation concerns whether Silverback and certain of its officers and/or directors have violated federal securities laws.

 

On or around December 3, 2020, Silverback conducted its initial public offering (“IPO”), offering 11.5 million shares of common stock priced at $21.00.  Then, on September 13, 2021, Silverback issued a press release “announc[ing] that interim data from the dose-escalation portion of its Phase 1/1b clinical trial evaluating SBT6050 as a monotherapy and in combination with pembrolizumab in patients with advanced or metastatic HER2-expressing or amplified solid tumors will be presented at the upcoming European Society for Medical Oncology (ESMO) 2021 Congress from September 16-21, 2021” and advising that “[t]he accepted abstract . . . is now available on the ESMO website.”  Per the abstract, while there was a manageable safety profile for the Company’s experimental therapy, the best overall response was PR (n=1), SD (n=3), and PD (n=10).  On this news, Silberback’s stock price fell $4.54 per share, or 23.35%, to close at $14.90 per share on September 13, 2021.

 

If you are aware of any facts relating to this investigation, or purchased Silverback shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.